

MPAC meeting 13-15 March 2013

Declaration of Interests

All MPAC members participating in the meeting updated their declaration of interest, which was assessed by the WHO Secretariat.

Eleven members reported relevant interests, which are disclosed below. It was concluded that all members could take part in full in all of the discussions, except for six members who will act as observers in the sessions where they have a conflict of interest.

All the reported relevant interests are summarized below:

Salim Abdulla

- Receives research funding from MVI and is an author on the RTS,S Phase 3 trial manuscript. This interest was assessed as non-personal, specific and financially significant*. Dr. Abdulla will act as an observer in MPAC discussions related to RTS,S, and will have no involvement in decision-making related to policy for RTS,S.

Pedro Alonso

- Is an author on the RTS,S Phase 3 trial manuscript. This interest was assessed as non-personal, specific and financially significant*. Prof. Alonso will act as an observer in MPAC discussions related to RTS,S, and will have no involvement in decision-making related to policy for RTS,S.

Patricia Graves

- Receives research support in the form of ASAQ donations from Sanofi Aventis. This interest was assessed as non-personal, non-specific and financially significant*.

Brian Greenwood

- Receives research funding from the Malaria Vaccine Initiative for the RTS,S vaccine trial. This interest was assessed as non-personal, specific, and financially significant*. Prof. Greenwood will act as an observer in MPAC discussions related to RTS,S, and will have no involvement in decision-making related to policy for RTS,S.

Rose Leke

- Receives funding from Pfizer, as Chair of the Data Safety Management Committee (DMSB) of an IPTp trial of AZ-CQ. She is currently the Co-Principal Investigator on a project on IPTp in Cameroon funded by the National Institute of Allergy and Infectious Diseases (NIAID), USA. This interest was assessed as non-personal, non-specific and financially significant*.

Kevin Marsh

- Is on the scientific advisory board for the Novartis Vaccine Institute for Global Health and an author on the RTS,S Phase 3 trial manuscript. This interest was assessed as non-personal, specific, and financially significant*. At the current MPAC meeting, the session on RTS,S vaccine is for information only. For this reason, Prof. Marsh, as Chair of MPAC, will be allowed to facilitate the session. He will have no involvement in decision-making related to policy for RTS,S.

Sylvia Meek

- Is technical director of the Malaria Consortium which receives research funding from the Bill & Melinda Gates Foundation, DfID, AusAID, and CDC. This interest was assessed as being non-personal, non-specific, and financially significant*.

Allan Schapira

- Received consultancy fees from GH Tech, the Bill & Melinda Gates Foundation, World Bank, and the Swiss Tropical and Public Health Institute. This interest was assessed as being personal, non-specific, and financially significant*.

Laurence Slutsker

- Is an author on the RTS,S Phase 3 trial manuscript. This interest was assessed as non-personal, specific and not financially significant*. Dr. Slutsker will act as an observer in MPAC discussions related to RTS,S, and will have no involvement in decision-making related to policy for RTS,S.

Marcel Tanner

- Directs the Swiss Tropical and Public Health Institute which receives research funding from Novartis Institute for Tropical Diseases, SNF, Wellcome Trust, Malaria Vaccine Initiative and the Bill & Melinda Gates Foundation. This interest was assessed to be non-personal, non-specific, and financially significant*.
- Is an author on the RTS,S Phase 3 trial manuscript. This interest was assessed to be non-personal, specific and financially significant*. Prof. Tanner will act as an observer in MPAC discussions related to RTS,S, and will have no involvement in decision-making related to policy for RTS,S.

Neena Valecha

- Directs the National Institute of Malaria Research - New Delhi, which receives research funding from companies: BASF, Sumitomo, Vestergaard, Bayer, and Syngenta. This interest was assessed to be non-personal, non-specific and financially significant*.

* According to WHO's Guidelines for Declaration of Interests (WHO expert), an interest is considered "personal" if it generates financial or non-financial gain to the expert, such as consulting income or a patent. "Specificity" states whether the declared interest is a subject matter of the meeting or work to be undertaken. An interest has "financial significance" if the honoraria, consultancy fee or other received funding, including those received by expert's organization, from any single malaria-related company exceeds 10,000 USD in a calendar year. Likewise, a shareholding in any one malaria-related company in excess of 1,000 USD would also constitute a "significant shareholding".

Last updated: 12 March 2012